Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

---

The aim of this study was to determine the role of donors’ ABCB1 G2677T/A polymorphism on tacrolimus dose requirements, trough levels and dose-adjusted trough concentrations among Jordanian renal transplant recipients during the early, unstable period post transplantation.Donors of those renal transplant recipients who were started on tacrolimus post-transplantation (n=53) were genotyped for MDR1 G2677T/A using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) analysis. Tacrolimus doses (mg/kg body weight), trough concentrations (ng/ml), dose-adjusted trough concentrations (ng/ml per mg/kg body weight) were compared among patients according to donors’ allelic status for MDR1 (G2677T/A). Among the 53 donors, 28 (52.8%) were carriers of GG, 20 (37.7%) of GT, and 5 (9.4%) of TT MDR1 alleles. Trough tacrolimus concentrations in recipients of donors carrying at least one T mutant alleles (2677TT or 2677GT, serine phenotype) did not differ significantly from trough concentration in recipients of donors carrying homozygote wild, 2677GG genotype (alanine) during the early 6 months post renal transplantation (P = 0.40, 0.62, 0.42, 0.60, 0.93, 0.66 for months 1-6, respectively). In conclusion, donor’s MDR1 gene polymorphism has no impact on trough tacrolimus concentration during the early period post-transplantation. To date, the results of studies remain controversial and many other factors must be considered to predict variability profile of trough tacrolimus levels accurately.

Keywords: Tacrolimus, dose requirements, trough levels, dose-adjusted trough concentrations

Full-Text [PDF 610 kb]   (2245 Downloads)    

Add your comments about this article : Your username or Email:

---